Safety and Dose Ranging Study of Insulin Receptor MAb-IDUA Fusion Protein in Patients With MPS I
Status:
Unknown status
Trial end date:
2017-06-01
Target enrollment:
Participant gender:
Summary
AGT-181 is a fusion protein containing alpha-L-Iduronidase that is intended to deliver the
enzyme peripherally and to the brain, when administered intravenously. This study is a safety
and dose ranging study to obtain safety and exposure data, as well as information on the
biological activity of the investigational drug.